Roche assumed with a Buy at Jefferies. Jefferies analyst Peter Welford assumed coverage of Roche with a Buy rating and CHF 300 price target. The analyst is positive on the European large-cap Pharma space “as it enters a period of sustained earnings momentum.” He calls Roche his most preferred EU large-cap Pharma name.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.